What is HC Wainwright’s Estimate for AnaptysBio Q1 Earnings?

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for AnaptysBio in a research report issued on Tuesday, November 11th. HC Wainwright analyst E. Bodnar anticipates that the biotechnology company will post earnings of ($0.88) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio’s Q3 2026 earnings at ($1.35) EPS and Q4 2026 earnings at ($1.29) EPS.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $1.58. The firm had revenue of $76.32 million during the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%.

ANAB has been the topic of several other research reports. Guggenheim boosted their target price on shares of AnaptysBio from $90.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. boosted their price objective on AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, July 24th. Truist Financial raised their target price on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday. UBS Group reiterated a “neutral” rating and issued a $20.00 target price (up from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. Finally, Wall Street Zen raised AnaptysBio from a “hold” rating to a “buy” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus price target of $59.40.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $33.56 on Wednesday. AnaptysBio has a 52 week low of $12.21 and a 52 week high of $40.96. The firm’s fifty day moving average is $29.35 and its 200-day moving average is $24.92. The firm has a market cap of $929.21 million, a P/E ratio of -11.90 and a beta of 0.16.

Institutional Trading of AnaptysBio

Hedge funds have recently bought and sold shares of the business. BIT Capital GmbH acquired a new position in AnaptysBio during the first quarter worth $473,000. HighMark Wealth Management LLC raised its holdings in shares of AnaptysBio by 58.2% in the 2nd quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock worth $3,231,000 after acquiring an additional 53,550 shares during the last quarter. Nuveen LLC acquired a new stake in shares of AnaptysBio in the 1st quarter worth about $1,041,000. First Light Asset Management LLC lifted its position in AnaptysBio by 433.3% in the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock valued at $86,139,000 after acquiring an additional 3,764,720 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ acquired a new position in AnaptysBio during the 1st quarter valued at about $623,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.